Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Free Cash Flow (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Free Cash Flow for 14 consecutive years, with -$11.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 53.64% year-over-year to -$11.8 million, compared with a TTM value of -$18.5 million through Dec 2025, up 80.86%, and an annual FY2025 reading of -$32.2 million, up 66.74% over the prior year.
  • Free Cash Flow was -$11.8 million for Q4 2025 at Enanta Pharmaceuticals, down from -$7.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $17.4 million in Q2 2025 and bottomed at -$36.7 million in Q4 2022.
  • Average Free Cash Flow over 5 years is -$19.8 million, with a median of -$21.8 million recorded in 2021.
  • The sharpest move saw Free Cash Flow tumbled 530.72% in 2021, then skyrocketed 192.61% in 2025.
  • Year by year, Free Cash Flow stood at -$13.6 million in 2021, then tumbled by 169.33% to -$36.7 million in 2022, then rose by 29.81% to -$25.8 million in 2023, then grew by 0.89% to -$25.5 million in 2024, then skyrocketed by 53.64% to -$11.8 million in 2025.
  • Business Quant data shows Free Cash Flow for ENTA at -$11.8 million in Q4 2025, -$7.9 million in Q3 2025, and $17.4 million in Q2 2025.